Back to top
more

Cencora, Inc. (COR)

(Delayed Data from NYSE)

$237.65 USD

237.65
1,133,443

+1.43 (0.61%)

Updated Sep 12, 2024 04:00 PM ET

After-Market: $237.69 +0.04 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 31% (173 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Should iShares Russell Mid-Cap Growth ETF (IWP) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IWP

Here's Why Cencora (COR) is a Strong Growth Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Is Cencora (COR) Down 2.8% Since Last Earnings Report?

by Zacks Equity Research

Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Cencora (COR) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Cencora (COR) Gains 16.6% YTD: What's Driving the Stock?

by Zacks Equity Research

Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.

Why Cencora (COR) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now

by Zacks Equity Research

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Here's Why Cencora (COR) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Cencora (COR) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

All You Need to Know About Cencora (COR) Rating Upgrade to Buy

by Zacks Equity Research

Cencora (COR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Compared to Estimates, Cencora (COR) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Cencora (COR) Q3 Earnings Beat Estimates, '24 View Raised

by Zacks Equity Research

Cencora's (COR) third-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Cencora (COR) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Cencora (COR) delivered earnings and revenue surprises of 5.03% and 0.90%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

Will These 4 MedTech Stocks Beat Forecasts This Earnings Season?

by Indrajit Bandyopadhyay

Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, XRAY, GEHC and GKOS are placed ahead of their earnings release.

Can Cigna (CI) Beat Q2 Earnings on Growing Pharmacy Revenues?

by Zacks Equity Research

Cigna's (CI) second-quarter earnings are expected to benefit from rising premiums and pharmacy revenues, partially offset by rising expenses.

Why Cencora (COR) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Cencora (COR) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Countdown to Cencora (COR) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Evaluate the expected performance of Cencora (COR) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Cencora (COR) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

Cencora's (COR) third-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.

Natera (NTRA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Natera (NTRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Do Options Traders Know Something About Cencora (COR) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Cencora (COR) stock based on the movements in the options market lately.

Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.